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Emerging considerations 




Incomplete recovery following reversal of neuromuscular blockade can present as a clinical problem in surgical patients. 
Emerging pharmacologic solutions may prevent such adverse outcomes in the future.  We briefly review two methods of 
pharmacologic reversal of neuromuscular blockade.  Both methods of reversal are effective. However the early studies of 
the new compound, sugammadex has been shown to achieve a more rapid, stable reversal of steroidal based neuromus-
cular blocking agents compared to neostigmine. Due to the novel mechanism of action of this agent, sugammadex has 
been demonstrated to be effective even when administered during profound neuromuscular block, without evidence of 
recurarization.
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Spontaneous recovery from neuromus-
cular block occurs through redistribu-
tion, buffered diffusion, or metabolism 
of the neuromuscular blocking agent 
(NMBA) administered (1) Acetylcho-
linesterase inhibitors (e.g. neostigmine) 
are often given at the end of surgery to 
speed the rate of recovery from non-
depolarizing NMBAs. However, residu-
al block may persist.  In the absence of 
such reversal agents, residual paralysis 
may persist for 2 hours or more after the 
administration of an intermediate dura-
tion muscle relaxant. (2) Concomitant 
use of magnesium (3), local anesthet-
ics (4), antibiotics (5-8), and calcium 
channel blockers (9) has also been 
shown to increase the risk of prolonged 
paralysis after reversal of neuromuscu-
lar blockade.  
Residual block may be associated with 
serious adverse events, such as res-
piratory depression, pharyngeal dys-
function, hypoxemia and prolonged 
length of stay in the recovery room. (10) 
While the use of acetylcholinesterase 
inhibitors may reduce these risks by 
accelerating reversal of neuromuscular 
blockade, they are themselves associ-
ated with unwanted effects resulting 
from muscarinic receptor activation. 
(11) Co-administration of anticholiner-
gic agents (e.g. glycopyrrolate) may 
attenuate these effects but at the poten-
tial cost of further side effects, such as 
tachycardia and QT interval prolonga-
tion. (12,13)
Sugammadex (Organon, USA Inc.) is a 
new reversal agent currently under clini-
cal investigation. A modified gamma 
cyclodextrin, sugammadex is a selec-
tive relaxant binding agent (SRBA) spe-
cifically designed to reverse the effects 
of the aminosteroidal non-depolarizing 
NMBA, rocuronium. Unlike the acetyl-
cholinesterase inhibitors, sugammadex 
does not achieve reversal via competi-
tive cholinergic mechanisms but, rath-
er, acts non-competitively by forming a 
complex with rocuronium, thereby low-
ering its effective concentration. (14) As 
a result, sugammadex does not require 
the co-administration of anticholinergic 
agents for the management of mus-
carinic side effects. 
Pharmacology
Pharmacological considerations ex-
plain the clinical differences between 
the two agents with regard to the onset 
and stability of reversal. Acetylcho-
linesterase inhibitors are agonists that 
act indirectly to increase endogenous 
concentrations of acetylcholine. This 
excess acetylcholine competes with the 
non-depolarizing NMBA at the nicotinic 
receptor at the neuromuscular junc-
tion. At the same time, these agents 
inevitably increase the availability of 
acetylcholine at muscarinic receptors, 
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resulting in parasympathetic adverse 
effects such as bradycardia and hyper-
salivation. Furthermore, there is a 
relative “ceiling effect” with acetylcho-
linesterase inhibitors, such that some 
recovery of neuromuscular function is 
required prior to their administration. 
(15) If these conventional agents are 
given to patient with a higher degree of 
neuromuscular blockade, inadequate 
reversal may ensue.
Sugammadex is a selective relaxant 
binding agent (SRBA) that is pharmaco-
logically unrelated to conventional meth-
ods of reversal. Since its mechanism of 
action does not involve an endogenous 
increase in acetylcholine, reversal of 
neuromuscular block by sugammadex 
is not accompanied by the side effects 
associated with acetylcholinesterase 
inhibitors. (16)  Sugammadex acts, 
instead, by encapsulating the NMBA, 
lowering its effective concentration. (17) 
By acting as a “pharmacologic sink”, 
sugammadex prevents the interaction 
between the aminosteroidal NMBA and 
the nicotinic receptor at the neuromus-
cular junction. (18) Due to the specificity 
of the sugammadex molecule, NMBAs 
of the benzylisoquinolinium class are 
not antagonized.
Clinical Trials
Several clinical studies have illustrated 
the effectiveness of this mechanism of 
action for rapid reversal of rocuronium-
induced neuromuscular blockade with-
out evidence of recurarization.  Efficacy 
was measured by acceleromyography 
(figure 1) and the time to achieve the 
train of four (TOF) ratio of 0.9 was the 
endpoint. Gijsenbergh et al.(19) showed 
full reversal without recurarization within 
2 min, when sugammadex 8mg/kg was 
administered 3 min after rocuronium 
0.6mg/kg. Other studies have demon-
strated similar efficacy with sugamma-
dex at doses of 2.0 mg/kg or higher, 
administered at reappearance of T2 fol-
lowing rocuronium 0.6 mg/kg. (20,21)  
The onset and stability of reversal with 
sugammadex appear to be related 
to several factors: the dose of NMBA 
administered, the timing of sugamma-
dex administration in relation to NMBA 
administration, and the dose of sug-
ammadex. In a dose-finding study by 
Groudine et al. (22), the two lowest 
doses of sugammadex (0.5 and 1.0mg/
kg) were found to achieve inadequate 
reversal of profound neuromuscular 
block. Although there was some varia-
bility in effectiveness between the doses 
administered in this study, reversal of 
profound rocuronium-induced block 
was more successful with sugamma-
dex ≥ 2 mg/kg. Low-dose sugamma-
dex was also the topic of a recent case 
report (23) which described a transient 
decrease in train of four (TOF) response 
after a small dose (0.5mg/kg) of sug-
ammadex for reversal of neuromuscu-
lar block induced by rocuronium 0.9 
mg/kg. Using the data from this patient, 
the investigators developed a simple 
pharmacokinetic-pharmacodynamic 
model of rocuronium, sugammadex 
and their interaction. Simulations using 
this model indicated that rebound of 
muscle relaxation may occur with sug-
ammadex doses “in a limited critical 
range”. The authors concluded that 
administration of sugammadex in a suf-
ficiently large dose eliminates the pos-
sibility of muscle relaxation rebound. 
In a direct comparison, sugammadex 
4 mg/kg has been shown to reverse 
rocuronium-induced neuromuscular 
blockade more rapidly and effectively 
compared with neostigmine 70 μg/kg 
or edrophonium 1 mg/kg. (24) It has 
also been demonstrated that revers-
al of neuromuscular block achieved 
with sugammadex does not depend 
on the type of anesthetic maintenance 
employed. Vanacker et al. (25) studied 
reversal of rocuronium with sugam-
madex in patients receiving either pro-
pofol or sevoflurane, and found the 
recovery time of the TOF ratio to 0.9 
to be comparable in both groups. In 
contrast, neostigmine has been shown 
to achieve slower reversal of rocuro-
nium-induced block under sevoflurane 
compared to propofol anesthesia. (26) 
Discussion
Recovery of the TOF ratio to 0.9 prior 
to tracheal extubation has been clini-
cally advocated as important for patient 
safety. (2,27,28) Although the incidence 
Figure 1. Acceleromyographic tracing example of the reversal of a rocuronium-induced neuromuscular block with sug-
ammadex under general anesthesia.  Vertical lines indicate T1 height. Dots indicate train-of-four (TOF) ratio.
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of “recurarization” declined with the 
introduction of shorter acting NMBAs 
in the 1990s (29), residual curarization 
may still occur. (30) In order to avoid 
complications related to the use of 
muscle relaxants, precise assessment 
of neuromuscular transmission would 
be beneficial. (31,32)  However, accel-
eromyography is not currently used 
routinely to determine a TOF ratio but 
remains primarily a tool for research. 
More conventional spot monitoring with 
TOF stimulation is unlikely to provide 
the clinician with an adequate assess-
ment of peri-operative neuromuscular 
function. The availability of a reversal 
agent with predictable effectiveness, 
and which fully prevents residual block, 
is therefore highly desirable.  
Conclusions
The pharmacological comparison 
described here illustrates the rapid 
recovery of neuromuscular function 
permitted by the novel mechanism of 
action of sugammadex. Studies have 
also demonstrated the ability of sug-
ammadex to reverse profound neu-
romuscular blockade, such that timing 
of sugammadex administration is not 
an issue, as it is with the use of con-
ventional reversal agents. The rapid 
reversal can be attributed to the sta-
bility of the complex formed between 
sugammadex and the aminosteroidal 
NMBA. In conclusion, with the arrival of 
sugammadex in clinical practice, resid-
ual neuromuscular block may become 
extinct as a clinical feature. 
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